Lead Pharma has entered into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune mediated diseases.
In this single target research collaboration, the two companies will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for further development and global commercialization.
Lead Pharma will receive an upfront payment of €10 million, and will be eligible to receive research funding and pre-clinical milestone payments; total potential payments including research, development, regulatory and sales milestones may add up to an aggregate of €260 million, plus royalties on worldwide sales.
Arthur Oubrie, Chief Scientific Officer of Lead Pharma, said: “This is the second project we partner with one of the largest pharmaceutical companies under our Discover, Design and Deliver platform.
“Our rigorous target selection process, translational screening cascade, and smart medicinal chemistry have been essential to bring this project to this stage. We are keen to collaborate with our colleagues at Roche to bring this novel approach to patients.”